Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

35
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of dried blood spot and umbilical cord blood samples for the quantification of maternally transferred IgG against the group B streptococcal alpha-like surface proteins in neonates at Kolding Hospital, Denmark: a proof-of-concept, cross-sectional study.

The Lancet. Microbe·2026
Same author

Systematic literature review on pneumococcal vaccination recommendations in national immunization programs for the pediatric population in select areas in the Asia Pacific region.

Human vaccines & immunotherapeutics·2026
Same author

Revisiting definitions of hypervirulent and classical Klebsiella pneumoniae through virulence factors and disease phenotype.

Communications medicine·2026
Same author

Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis.

Vaccine·2026
Same author

SARS-CoV-2 seroprevalence among pregnant women during the first three waves of the COVID-19 pandemic in southern Mozambique.

BMC pregnancy and childbirth·2026
Same author

Safety and efficacy of faecal microbiota transplantation in Parkinson's disease.

NPJ Parkinson's disease·2026
Same journal

Immunity gaps for several vaccine preventable diseases in Norway.

Vaccine·2026
Same journal

Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey.

Vaccine·2026
Same journal

Immunoproteomics and reverse vaccinology identify a protective T-cell epitope from Fonsecaea pedrosoi for experimental chromoblastomycosis.

Vaccine·2026
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

14.4K

Vaccine value profile for Group B streptococcus.

Caroline L Trotter1, Mark Alderson2, Ziyaad Dangor3

  • 1Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK.

Vaccine
|November 11, 2023
PubMed
Summary
This summary is machine-generated.

Group B Streptococcus (GBS) vaccines are crucial for preventing infant deaths and stillbirths globally. This Vaccine Value Profile assesses available data to guide the development and public health impact of new GBS vaccines.

Keywords:
Group B streptococcusVaccine value profileVaccines, maternal immunisation

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Related Experiment Videos

Last Updated: Jul 11, 2025

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

14.4K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Area of Science:

  • Vaccinology
  • Maternal and Child Health
  • Infectious Disease Epidemiology

Background:

  • Group B Streptococcus (GBS) causes significant neonatal meningitis, sepsis, and pneumonia, leading to high infant mortality and stillbirth rates.
  • GBS infections during pregnancy are linked to adverse maternal outcomes and preterm births, highlighting a critical global health challenge.
  • The World Health Organization (WHO) prioritizes GBS vaccine development for pregnant women, especially in low- and middle-income countries (LMICs) with the highest disease burden.

Purpose of the Study:

  • To provide a holistic assessment of available information and data for Group B Streptococcus (GBS) pipeline vaccines.
  • To inform the potential public health, economic, and societal value of GBS vaccines and vaccine-like products.
  • To identify current research and knowledge gaps in GBS vaccine development and implementation.

Main Methods:

  • Development of a Vaccine Value Profile (VVP) for GBS.
  • Compilation and assessment of existing, publicly available information and data.
  • Collaboration with a working group of subject matter experts and stakeholders from various global regions and organizations.

Main Results:

  • The VVP provides a high-level overview of the current landscape of GBS vaccine development.
  • The assessment utilizes existing data to evaluate the potential value of pipeline GBS vaccines.
  • Key research and knowledge gaps relevant to GBS vaccine implementation have been identified.

Conclusions:

  • A comprehensive understanding of the potential value of GBS vaccines is essential for guiding future development and public health strategies.
  • The VVP serves as a critical resource for stakeholders involved in GBS vaccine initiatives.
  • Addressing identified knowledge gaps will be crucial for the successful licensure and equitable deployment of GBS vaccines, aligning with the WHO's Defeating Meningitis by 2030 targets.